Analysts See $-0.09 EPS for CareDx, Inc (CDNA)

July 21, 2018 - By Jenna Rose

Investors sentiment decreased to 3.14 in Q1 2018. Its down 3.00, from 6.14 in 2017Q4. It is negative, as 2 investors sold CareDx, Inc shares while 12 reduced holdings. 21 funds opened positions while 23 raised stakes. 36.48 million shares or 30.74% more from 27.90 million shares in 2017Q4 were reported.
79,000 are owned by Macquarie Grp Limited. Emerald Mutual Fund Advisers has 0.14% invested in CareDx, Inc (NASDAQ:CDNA). Vanguard Grp Inc Inc Inc owns 845,962 shares. Goldman Sachs Grp Incorporated invested in 0% or 75,807 shares. 160,152 are held by Millennium Llc. Cambridge Investment Research reported 0.01% in CareDx, Inc (NASDAQ:CDNA). Clear Harbor Asset Mngmt reported 28,800 shares stake. Moreover, Citadel Advsr has 0% invested in CareDx, Inc (NASDAQ:CDNA). Woodmont Investment Counsel Ltd Liability holds 0.2% or 91,055 shares in its portfolio. Wellington Management Group Incorporated Llp, Massachusetts-based fund reported 1.17M shares. Wells Fargo And Mn, a California-based fund reported 16,980 shares. Products Prtnrs Ltd invested 0.01% of its portfolio in CareDx, Inc (NASDAQ:CDNA). Bank Of Montreal Can holds 0% in CareDx, Inc (NASDAQ:CDNA) or 17,806 shares. 37,373 are held by Friess Assoc Llc. Moreover, Trexquant Inv Limited Partnership has 0.04% invested in CareDx, Inc (NASDAQ:CDNA).

Since March 27, 2018, it had 1 buy, and 2 selling transactions for $517,465 activity. GAGNON NEIL bought $95,481 worth of stock. Another trade for 39,649 shares valued at $494,911 was made by Nelles Mitchell J on Friday, June 29.

Analysts expect CareDx, Inc (NASDAQ:CDNA) to report $-0.09 EPS on August, 9.They anticipate $0.10 EPS change or 52.63 % from last quarter’s $-0.19 EPS. After having $-0.16 EPS previously, CareDx, Inc’s analysts see -43.75 % EPS growth. It closed at $12.49 lastly. It is down 1044.55% since July 21, 2017 and is uptrending. It has outperformed by 1031.98% the S&P500.

CareDx, Inc (NASDAQ:CDNA) Ratings Coverage

Among 2 analysts covering CareDx (NASDAQ:CDNA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. CareDx had 9 analyst reports since January 31, 2018 according to SRatingsIntel. Piper Jaffray maintained CareDx, Inc (NASDAQ:CDNA) on Thursday, March 22 with “Buy” rating. The firm has “Hold” rating by H.C. Wainwright given on Tuesday, June 19. The rating was maintained by H.C. Wainwright on Wednesday, January 31 with “Buy”. H.C. Wainwright maintained the shares of CDNA in report on Thursday, April 12 with “Buy” rating. On Wednesday, June 6 the stock rating was maintained by Piper Jaffray with “Buy”. The stock of CareDx, Inc (NASDAQ:CDNA) earned “Buy” rating by Piper Jaffray on Monday, May 21. The firm has “Buy” rating given on Friday, May 11 by H.C. Wainwright. The firm has “Buy” rating given on Monday, April 2 by H.C. Wainwright. H.C. Wainwright maintained CareDx, Inc (NASDAQ:CDNA) on Friday, March 23 with “Buy” rating.

CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company has market cap of $440.69 million. The firm operates through two divisions, CareDx and Olerup. It currently has negative earnings. The Company’s commercialized testing solution includes the AlloMap heart transplant molecular test , a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection.

More recent CareDx, Inc (NASDAQ:CDNA) news were published by: which released: “Flatiron Health CMO/CSO Joins CareDx Board of Directors” on June 28, 2018. Also published the news titled: “Here’s Why CareDx Dropped Today” on June 22, 2018.‘s news article titled: “CareDx to Announce Second Quarter 2018 Financial Results on August 9, 2018” with publication date: July 16, 2018 was also an interesting one.

CareDx, Inc (NASDAQ:CDNA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.